Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment
- PMID: 1149368
- DOI: 10.1002/cpt1975182180
Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment
Abstract
The biologic disposition of methadone in acute and during chronic administration was studied in 12 human volunteers. In the acute study a biexponential methadone plasma level decay was observed. The acute primary half-life (t1/2) of 14.3 hr in combination with the acute secondary t1/2 of 54.8 hr were longer than the single exponential chronic t1/2 of 22.2 hr determined in the same subjects. The urinary and fecal excretion of methadone and its mono-N-demethylated metabolite increased from 22.2% in the acute to 62.0% in the chronic phase of the study. The urinary metabolite 1 to methadone ratio tripled from the acute to the chronic phase. The pupillary effects of methadone monitored throughout 24 hr were nearly the same in magnitude in the acute and the chronic studies, whereas the plasma levels increased 3- to 8-fold following chronic methadone administration. These findings suggest that both dispositional and pharmacologic tolerance are involved in the development of tolerance following chronic administration of methadone.
Similar articles
-
The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.Clin Pharmacokinet. 1976;1(3):219-30. doi: 10.2165/00003088-197601030-00004. Clin Pharmacokinet. 1976. PMID: 13957 Review.
-
Disposition of methadone in man after a single oral dose.Clin Pharmacol Ther. 1972 Nov-Dec;13(6):923-30. doi: 10.1002/cpt1972136923. Clin Pharmacol Ther. 1972. PMID: 5081605 No abstract available.
-
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.Clin Pharmacol Ther. 1976 Sep;20(3):315-28. doi: 10.1002/cpt1976203315. Clin Pharmacol Ther. 1976. PMID: 954353
-
Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method.Eur J Clin Pharmacol. 1981;20(6):473-8. doi: 10.1007/BF00542102. Eur J Clin Pharmacol. 1981. PMID: 7286059
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
Cited by
-
[Presence of methadone in apocrine sweat of the human].Z Rechtsmed. 1990;103(5):323-7. doi: 10.1007/BF01263036. Z Rechtsmed. 1990. PMID: 2356661 German.
-
Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.Clin Pharmacokinet. 2002;41(14):1153-93. doi: 10.2165/00003088-200241140-00003. Clin Pharmacokinet. 2002. PMID: 12405865 Review.
-
Analgesie mit Methadon.Schmerz. 1989 Sep;3(3):155-65. doi: 10.1007/BF02527398. Schmerz. 1989. PMID: 18415356 German. No abstract available.
-
Mechanism of autoinduction of methadone N-demethylation in human hepatocytes.Anesth Analg. 2013 Jul;117(1):52-60. doi: 10.1213/ANE.0b013e3182918252. Epub 2013 Jun 3. Anesth Analg. 2013. PMID: 23733841 Free PMC article.
-
Pharmacokinetics of methadone during maintenance therapy: pulse labeling with deuterated methadone in the steady state.Eur J Clin Pharmacol. 1979 Aug;16(1):53-7. doi: 10.1007/BF00644967. Eur J Clin Pharmacol. 1979. PMID: 499301